Riemekasten, Gabriela

Update of EULAR recommendations for the treatment of systemic sclerosis

Kowal-Bielecka, O., Fransen, J., Avouac, J., Becker, M., Kulak, A., Allanore, Y., Distler, O., Clements, P., Cutolo, M., Czirjak, L., et al. (2017) · Annals of the Rheumatic Diseases

Systemic Sclerosis and Related DiseasesPulmonary Hypertension Research and Treatments

Cited by 1,104

Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial

Khanna, D., Denton, C. P., Jahreis, A., van Laar, J. M., Frech, T. M., Anderson, M. E., Baron, M., Chung, L., Fierlbeck, G., Lakshminarayanan, S., et al. (2016) · The Lancet

Systemic Sclerosis and Related DiseasesRheumatoid Arthritis Research and Therapies

Cited by 683

Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)

Khanna, D., Denton, C. P., Lin, C. J. F., van Laar, J. M., Frech, T. M., Anderson, M. E., Baron, M., Chung, L., Fierlbeck, G., Lakshminarayanan, S., et al. (2018) · Annals of the Rheumatic Diseases

Systemic Sclerosis and Related DiseasesConnective tissue disorders research

Cited by 265

Unmet medical needs in chronic, non-communicable inflammatory skin diseases

Ujiie, H., Rosmarin, D., Schön, M. P., Ständer, S., Boch, K., Metz, M., Maurer, M., Thaci, D., Schmidt, E., Cole, C., et al. (2022) · Frontiers in Medicine

Dermatology and Skin DiseasesPsoriasis: Treatment and Pathogenesis

Cited by 158

BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in Caucasians

Rueda, B., Gourh, P., Broen, J., Agarwal, S. K., Simeon, C., Ortego-Centeno, N., Vonk, M. C., Coenen, M., Riemekasten, G., Hunzelmann, N., et al. (2010) · Annals of the Rheumatic Diseases

Systemic Sclerosis and Related DiseasesConnective tissue disorders research

Cited by 108